<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e>, including its ischemic sequelae, remains a leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> and disability following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to evaluate whether the low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) enoxaparin reduces the occurrence of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> following spontaneous SAH </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A prospective, double-blind, randomized study was conducted in 120 consecutive patients with SAH (Hunt Hess Scale (HHS) I-III) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients received one subcutaneous injection per day of either 20mg enoxaparin or placebo for 3 weeks following SAH </plain></SENT>
<SENT sid="4" pm="."><plain>Efficacy endpoints were the occurrence of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, delayed ischemic deficit (DID), <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>, and overall outcome at 1 year following SAH </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At 1-year follow-up, enoxaparin significantly reduced DID and <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Delayed ischemic deficit occurred in 8.8% of the enoxaparin group versus 66.7% of the placebo group (P&lt;0.001), while 3.5% of vasospasm-related <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarctions</z:e> occurred in enoxaparin-treated patients and 28.3% in placebo-treated patients (P&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Severe shunt-dependent <z:hpo ids='HP_0000238'>hydrocephalus</z:hpo> was significantly lower in the enoxaparin group (1.8% versus 16.7%; P=0.019) </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with the placebo group, the enoxaparin group had fewer <z:mp ids='MP_0001915'>intracranial bleeding</z:mp> events and better overall outcomes at 1-year follow-up </plain></SENT>
<SENT sid="9" pm="."><plain>Although there was potential bias as a result of patients in the placebo group being more severely affected (in terms of HHS), treatment with enoxaparin for 3 weeks improved long-term outcome following SAH </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Enoxaparin is safe and effective in reducing <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> following SAH (Hunt Hess grades I-III), resulting in a better long-term outcome for the patient </plain></SENT>
</text></document>